Original GlobalMD Global Physicians Organization 2024-05-14 06:30 United States
Read the digest
Researchers at the Karolinska Institute in Sweden have demonstrated the great potential and benefits of advanced technologies in "digital twins" in tailoring drug treatments for immune diseases such as rheumatoid arthritis.
Researchers are using digital technology and AI algorithms to innovate a "digital twin" approach that analyzes and simulates treatment outcomes and responses to conditions by creating a digital twin of each patient. These digital twins are able to depict and manipulate in detail the interactions of thousands of genes across various cell types, providing predictions for personalized precision treatments.
Over the past five years, the research team has been working to translate patient-specific disease mechanisms into actionable digital models. With this digital twin model, clinicians can fine-tune to enhance or inhibit disease treatments by precisely targeting key "switch" proteins that affect disease processes.
Compared to the traditional "one-size-fits-all" approach to drug treatment, this digital twin-guided approach provides more precise drug selection, improving treatment effectiveness and reducing side effects.
By studying the application of digital twin technology, the researchers hope to apply this digital technology to other clinical disease research and precision treatment fields, truly realize personalized treatment, and bring new treatment hope and effects to patients suffering from various autoimmune diseases
